The role of vasoactive drugs in the treatment of oesophageal varices

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 2, 2004, Pages 349-360

  D'Amico, Gennaro ^a  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

Oesophageal varices; Portal hypertension; Variceal bleeding; Vasoactive drugs

Indexed keywords

2 PYRIDYLCARBAMIC ACID 2 [[5 (2 METHOXYPHENOXY) 6 [[(4 ISOPROPYLPHENYL)SULFONYL]AMINO] 2 MORPHOLINO 4 PYRIMIDINYL]OXY]ETHYL ESTER; 2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; ANGIOPEPTIN; BOSENTAN; CAPTOPRIL; CARVEDILOL; CLONIDINE; DARUSENTAN; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; LOSARTAN; NADOLOL; NCX 1000; NIPRADILOL; OCTREOTIDE; PRAZOSIN; PROPRANOLOL; SOMATOSTATIN; SPIRONOLACTONE; TERLIPRESSIN; TIMOLOL; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID DERIVATIVE; VAPREOTIDE; VASOACTIVE AGENT; VASOPRESSIN;

ABDOMINAL CRAMP; ANGINA PECTORIS; ASCITES; BLEEDING; BRADYCARDIA; BRONCHOSPASM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESOPHAGUS VARICES BLEEDING; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INTESTINE NECROSIS; KIDNEY DYSFUNCTION; LIMB ISCHEMIA; LIVER CIRCULATION; LIVER TOXICITY; MESENTERY DISEASE; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SPLANCHNIC BLOOD FLOW; TISSUE NECROSIS; VASCULAR RESISTANCE;

EID: 1242319261     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.2.349     Document Type: Review

References (82)

1. GARCIA-TSAO G, GROSZMANN RJ, FISHER RL, CONN HO, ATTERBURY CE, GLICKMAN M: Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology (1985) 5:419-424.
2. CASADO M, BOSCH J, GARCIA-PAGAN JC, BRU C et al.: Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings: Gastroenterology (1998) 114:1296-1303.
3. D'AMICO G, PAGLIARO L, BOSCH J: Pharmacological treatment of portal hypertension: an evidence-based approach: Semin. Liver Dis. (1999) 19:475-505.
4. PINZANI M, GENTILINI P: Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin. Liver Dis. (1999) 19:397-410.
5. WIEST R, GROSZMANN RJ: The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology (2002) 35:478-491.
6. BENOIT JN, BARROWMAN JA, HARPER SL, KVIETYS PR, GRANGER DN: Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension: Am. J. Physiol. (1984) 247:G486-G493.
7. WIEST R, GROSZMANN RJ: Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin. Liver Dis. (1999) 19:411-426.
8. GROSZMANN RJ: Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences (editorial comment). Hepatology (1994) 20:1359-1363.
9. D'AMICO G, PAGLIAR0 L: The clinical course of portal hypertension in liver cirrhosis. In: Portal hypertension. Diagnostic imaging and imaging guided therapy. Rossi P (Ed.), Springer Verlag, Berlin (2000):15-24.
10. D'AMICO G, DE FRANCHIS R: Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology (2003) 38:599-612.
11. GROSZMANN RJ, GARCIA-TSAO G, BOSCH J et al.: Multicenter randomized placebo controlled trial of non selective beta-blockers in the prevention of the complications of portal hypertension. Final results and identification of a predictive factor. Proceedings of the annual meeting of the American Association for the Study of the Liver (AASLD), Boston, USA (October 2003), Abstract 103.
12. MERKEL C, MARIN R, ANGELI P et al.: Beta-blockers in the prevention of aggravation of esophageal varices in patients with cirrhosis and small varices: a placebocontrolled clinical trial. Proceedings of the annual meeting of the American Association for the Study of the Liver (AASLD), Boston, USA (October 2003) (Abstract 127).
13. GROSZMANN RJ, BOSCH J, GRACE ND et al.: Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology (1990) 99:1401-1407.
14. FEU F, GARCIA-PAGAN JC, BOSCH J et al.: Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet (1995) 346:1056-1059.
15. GARCIA-PAGAN JC, FEU F, NAVASA M et al.: Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. J. Hepatol. (1990) 11:189-195.
16. MORILLAS RM, PLANAS R, CABRE E, GALAN A, QUER JC, FEU F et al.: Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology (1994) 20:1502-1508.
17. ALBILLOS A, BANARES R, BARRIOS C et al.: Oral administration of clonidine in patients with alcoholic cirrhosis: Hemodynamic and liver function effects. Gastroenterology (1992) 102:248-254.
18. LEBREC D, NOUEL O, BERNUAU J, BOUIGUES M, RUEFF B, BENHAMOU JP: Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet (1981) 1:920-921.
19. LEBREC D, HILLON P, MUNOZ C, GOLDFARB G, NOUEL O, BENHAMOU JP: The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology (1982) 2:523-527.
20. BOSCH J, MASTAI R, KRAVETZ Der et al.: Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology (1984) 4:1200-1205.
21. GARCIA-TSAO, G, GRACE ND, GROSZMANN RJ et al.: Short-term effects of propranolol on portal venous pressure. Hepatology (1986) 6:101-106.
22. ESCORSELL A, FERAYORNI L, BOSCH J et al.: The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology (1997) 112:2012-2016.
23. BOSCH J, BORDAS JM, MASTAI R et al.: Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: comparison with the effects on portal pressure: Hepatology (1988) 8:861-865.
24. BOSCH J, GROSZMANN RJ, GARCIA-PAGAN JC et al.: Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. Hepatology (1989) 10:962-968.
25. BOSCH J, LEBREC D, JENKINS SA: Development of analogues: successes and failures. Scand J. Gastroenterol. (1998) 226(Suppl.):3-13.
26. BOSCH J, KRAVETZ D, MASTAI R et al.: Effects of somatostatin in patients with portal hypertension. Horm. Res. (1988) 29:99-102.
27. CIRERA I, FEU F, LUCA A, GARCIA-PAGAN JC et al.: Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology (1995) 22:106-111.
28. MOITINHO E, PLANAS R, BANARES R et al.: Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J. Hepatol. (2001) 35:712-718.
29. ESCORSELL A, BANDI JC, ANDREU V et al.: Desensitization to the effects of intravenous Octreotide in cirrhotic patients with portal hypertension. Gastroenterology (2001) 120:161-169.
30. LUDWIG D, SCHADEL S, BRUNING A, SCHIEFER B, STANGE EF: 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study. Dig. Dis. Sci. (2000) 45:1019-1027.
31. GARCIA-PAGAN JC, FEU F, BOSCH J, RODES J: Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann. Intern. Med. (1991) 114:869-873.
32. ALBILLOS A, GARCIA-PAGAN JC, IBORRA J et al.: Propranolot plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology (1998) 115:116-123.
33. ABRACZINSKAS DR, OOKUBO R, GRACE ND et al.: Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? Hepatology (2001) 34:1096-1102.
34. SPIEGEL B, TARGOWNIK L, DULAI GS, KARSAN HA, GRALNEK IM: Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective? Hepatology (2003) 37:366-377.
35. GARCIA-PAGAN JC, VILLANUEVA C, VILA MC et al.: Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β-blockers. Gastroenterology (2001) 121:908-914.
36. GARCIA-PAGAN JC, ESCORSELL A, MOITINHO E, BOSCH J: Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin. Liver Dis. (1999) 19:427-438.
37. PAGLIARO L, D'AMICO G, SORENSEN TI, LEBREC D BURROUGHS AK, MORABITO A: Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann. Intern. Med. (1992) 117:59-70.
38. IMPERIALE T, CHALASANI N: A meta-analysis of endoscopic variceal ligation for primary prophylaxis of variceal bleeding. Hepatology (2001) 33:802-807.
39. LUI HF, STANLEY AJ, FORREST HE, JALAN R, HISLOP WS, MILLS PR: Primary prophylaxis of variceal hemorrhage. A randomised controlled trial comparing band ligation, propranolol and isosorbide mononitrate. Gastroenterology (2002) 132:735-744.
40. SONG HI, SHIN JW, KIM IH: A prospective randomised trial between the prophylactic endoscopic variceal ligation and propranolol administration for prevention of first bleeding in cirrhotic patients with high risk esophageal varices. J. Hepatol. (2002) 32(Suppl. 2):41.
41. GHEORGHE C, GHEORGHE L, VADAN R: Prophylactic banding ligation of high risk esophageal varices in patients on the waiting list for liver transplantation: an interim report. Proceedings of the 37th Annual Meeting of the European Association for the Study of the Liver, Madrid, Spain (2002) (Abstract 114).
42. SARIN SK, LAMBA GS, KUMAR M, MISRA A, MURTHY NS: Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N. Engl. J. Med. 1999 340:988-993.
43. SCHEPKE M, GOEBEL C, NUERNBERG D, WILLERT J, KOCH L, SAUERBRUCH T: Endoscopic banding ligation versus propranolol for the primary prevention of variceal bleeding in cirrhosis: a randomised controlled multicenter trial. Proceedings of the annual meeting of the American Association for the Study of the Liver (AASLD), Boston, USA (October 2003) (Abstract 128).
44. PUGH RN, MURRAY-LYON IM, DAWSON JL, PIETRONI MC, WILLIAMS R: Transection of the esophagus for bleeding oesophageal varices. Br. J. Surg. (1973) 60:646-649.
45. BOSCH J, ABRALDES JC, GROSZMANN R: Current management of portal hypertension. J. Hepatol. (2003) 38:S54-S68.
46. IOANNOU G, DOUST J, ROCKEY DC: Terlipressin for acute esophageal variceal hemorrhage (Cochrane Review). In: The Cochrane Library Issue 3, Update Software, Oxford (2003).
47. IMPERIALE TF, TERAN JC, MCCULLOUGH AJ: A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology (1995) 109:1289-1294.
48. D'AMICO G, CRISCUOLI V, FILI'D, MOCCIARO F, PAGLIARO L: Metaanalysis of trials for variceal bleeding. Hepatology (2002) 36:1023-1024.
49. BURROUGHS AK: Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial failures. Hepatology (1996) 24:352A.
50. D'AMICO G, PIETROSI G, TARANTINO I, PAGLIAR0 L: Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology (2003) 124:1277-1291.
51. BANARES R, ALBILLOS A, RINCON D et al.: Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology (2002) 35:609-615.
52. DE FRANCHIS R: Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J. Hepatol. (2000) 33:846-852.
53. BERNARD B, LEBREC D, MATHURIN P, OPOLON P, POYNARD T: Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology (1997) 25:63-70.
54. GOURNAY J, MASLIAH C, MARTIN T, PERRIN D, GALMICHE JP: Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology (2000) 31:1239-1245.
55. PATTI R, PASTA L, D'AMICO G: Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of recurrent bleeding in cirrhosis. A double blind placebo controlled randomized trial. Final report. J. Hepatol. (2001) 34:64.
56. VILLANUEVA C, BALANZÒ J, NOVELLA M et al.: Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal bleeding. N. Engl. J. Med. (1996) 334:1624.
57. VILLANUEVA C, MINANA J, ORTIZ J, GALLEGO A, SORIANO G, TORRAS X et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding: N. Engl. J. Med. (2001) 345:647-655.
58. PATCH D, SABIN CA, GOULIS J et al.: A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology (2002) 123:1013-1019.
59. LO GH, CHEN WC, CHEN MH et al.: Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding: Gastroenterology (2002) 123:728-734.
60. ESCORSELL A, BANARES R, GARCIA-PAGAN JC et al.: TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology (2002) 35:385-392.
61. GRALNEK IM, JENSEN DM, KOVACS TOG et al.: The economic impact of esophageal variceal hemorrhage: cost-effectiveness implications of endoscopic therapy. Hepatology (1999) 29:44-50.
62. MERKEL C, MARIN R, SACERDOTI D et al.: Long term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2000) 31:324-329.
63. BUREAU C, PERON JM, ALRIC L et al.: "A la carte" treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology (2002) 36:1361-1366.
64. ABRALDES J, TARANTINO I, TURNES J, GARCIA-PAGAN JC, RODES J, BOSCH J: Hemodynamic response to pharmacologic treatment of portal hypertension and long term prognosis of cirrhosis. Hepatology (2003) 37:902-908.
65. ALBILLOS A, LLEDO JL, ROSSI I et al.: Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology (1995) 109:1257-1265.
66. BOSCH J, ARROYO V, BETRIU, MAS A, CARRILHO, F RIVERA FA et al.: Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology (1980) 78:92-99.
67. SCHNEIDER AW, FRIEDRICH J, KLEIN CP: Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology (1999) 29:334-339.
68. DEBERNARDI VENON W, BARONIO M et al.: Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study. J. Hepatol. (2003) 38:455-460.
69. JONSSON JR, CLOUSTON AD, ANDO Y et al.: Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology (2001) 121:148-155.
70. REICHEN J, GERBES AL, STEINER MJ, SAGESSER H, CLOZEL M: The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J. Hepatol. (1998) 28:1020-1030.
71. POO JL, JIMENEZ W, MARIA MUNOZ R et al.: Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology (1999) 116:161-167.
72. CHO JJ, HOCHER B, HERBST H et al.: An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology (2000) 118:1169-1178.
73. KOJIMA H, SAKURAI S, KURIYAMA S et al.: Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J. Hepatol. (2001) 34:805-811.
74. UM S, NISHIDA O, TOKUBAYASHI M, KIMURAF, KITA T: Nipradilol, a new beta-blocker with vasodilatory properties, in experimental portal hypertension: a comparative haemodynamic study with propranolol. J. Gastroenterol. Hepatol. (1993) 8:414-419.
75. ARAMAKI T, SEKIYAMA T, KATSUTA Y et al.: Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol. J. Hepatol. (1992) 15:48-53.
76. 1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology (1999) 30:79-83.
77. STANLEY AJ, THERAPONDOS G, HELMY A, HAYES PC: Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J. Hepatol. (1999) 30:479-484.
78. TRIPATHI D, THERAPONDOS G, LUI HF, STANLEY AJ, HAYES PC: Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment. Pharmacol. Ther. (2002) 16:373-380.
79. BANARES R, MOITINHO E, MATILLA A et al.: Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology (2002) 36:1367-1373.
80. MOAL F, VUILLEMIN E, WANG J: Crhonic antifibrotic and hemodynamic effects of a new liver specific NO donor (V-pyrro/NO) in bile duct ligated (BDL) rats. Hepatology (2001) 32:186A.
81. FIORUCCI S, ANTONELLI E, MORELLI O etal.: NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc. Natl. Acad. Sci. USA (2001) 98:8897-8902.
82. FORREST EH, JONES AL, DILLON JF, WALKER J, HAYES PC: The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. J. Hepatol. (1995) 23:254-258.